Ellen Sher

1.8k total citations
16 papers, 1.0k citations indexed

About

Ellen Sher is a scholar working on Physiology, Pulmonary and Respiratory Medicine and Immunology and Allergy. According to data from OpenAlex, Ellen Sher has authored 16 papers receiving a total of 1.0k indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Physiology, 6 papers in Pulmonary and Respiratory Medicine and 5 papers in Immunology and Allergy. Recurrent topics in Ellen Sher's work include Asthma and respiratory diseases (10 papers), Respiratory and Cough-Related Research (6 papers) and Allergic Rhinitis and Sensitization (5 papers). Ellen Sher is often cited by papers focused on Asthma and respiratory diseases (10 papers), Respiratory and Cough-Related Research (6 papers) and Allergic Rhinitis and Sensitization (5 papers). Ellen Sher collaborates with scholars based in United States, United Kingdom and Switzerland. Ellen Sher's co-authors include Wendy Surs, Donald Y.M. Leung, Stanley J. Szefler, S.J. Szefler, Donald Y.M. Leung, Alan K. Kamada, Sun Ying, Q Hamid, Richard J. Martin and A B Kay and has published in prestigious journals such as Journal of Clinical Investigation, The Journal of Experimental Medicine and The Journal of Immunology.

In The Last Decade

Ellen Sher

13 papers receiving 981 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Ellen Sher United States 7 626 328 283 183 147 16 1.0k
Wendy Surs United States 9 868 1.4× 388 1.2× 439 1.6× 309 1.7× 151 1.0× 12 1.5k
S.J. Szefler United States 6 300 0.5× 157 0.5× 181 0.6× 117 0.6× 43 0.3× 11 549
Edit Gyimesi Hungary 21 213 0.3× 424 1.3× 70 0.2× 48 0.3× 117 0.8× 40 1.1k
Cornelia Then Germany 16 127 0.2× 125 0.4× 108 0.4× 183 1.0× 93 0.6× 49 780
Lisa Cameron Canada 16 307 0.5× 286 0.9× 76 0.3× 28 0.2× 97 0.7× 30 655
Martin K. Oaks United States 16 105 0.2× 481 1.5× 52 0.2× 109 0.6× 15 0.1× 39 923
Matteo Borro Italy 9 281 0.4× 185 0.6× 42 0.1× 40 0.2× 83 0.6× 23 809
T Nakazawa Japan 15 148 0.2× 250 0.8× 81 0.3× 96 0.5× 18 0.1× 41 867
Anna Stasiak‐Barmuta Poland 14 110 0.2× 270 0.8× 87 0.3× 88 0.5× 31 0.2× 87 645
Wai Cheung United States 14 323 0.5× 152 0.5× 65 0.2× 29 0.2× 30 0.2× 18 854

Countries citing papers authored by Ellen Sher

Since Specialization
Citations

This map shows the geographic impact of Ellen Sher's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ellen Sher with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ellen Sher more than expected).

Fields of papers citing papers by Ellen Sher

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ellen Sher. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ellen Sher. The network helps show where Ellen Sher may publish in the future.

Co-authorship network of co-authors of Ellen Sher

This figure shows the co-authorship network connecting the top 25 collaborators of Ellen Sher. A scholar is included among the top collaborators of Ellen Sher based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ellen Sher. Ellen Sher is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

16 of 16 papers shown
1.
Corren, Jonathan, Stanley J. Szefler, Ellen Sher, et al.. (2024). Lebrikizumab in Uncontrolled Asthma: Reanalysis in a Well-Defined Type 2 Population. The Journal of Allergy and Clinical Immunology In Practice. 12(5). 1215–1224.e3. 18 indexed citations
2.
Sher, Ellen, Mark Boguniewicz, Jinglin Zhong, et al.. (2023). Efficacy of Lebrikizumab in Patients With Atopic Dermatitis and Atopic Comorbidities: Pooled Results From Two Phase 3 Monotherapy Randomized, Double-Blind, Placebo-Controlled 16-Week Studies (ADvocate1 and ADvocate2). Journal of Allergy and Clinical Immunology. 151(2). AB148–AB148. 2 indexed citations
3.
Sher, Ellen, et al.. (2022). Current and emerging therapies for eosinophilic esophagitis. Allergy and Asthma Proceedings. 43(3). 178–186. 4 indexed citations
4.
Siri, Dareen, et al.. (2020). Improved Tolerability and Continued Immunomodulation Among Subjects Aged 4-17 Years Following 12 or 18 Months of Daily Therapeutic AR101 Dosing. Journal of Allergy and Clinical Immunology. 145(2). AB133–AB133. 1 indexed citations
5.
Berger, William E., Ellen Sher, Sandra M. Gawchik, & Stanley M. Fìneman. (2018). Safety of a novel intranasal formulation of azelastine hydrochloride and fluticasone propionate in children: A randomized clinical trial. Allergy and Asthma Proceedings. 39(2). 110–116. 12 indexed citations
6.
Sher, Ellen, Abhishek Kavati, Dominic Pilon, et al.. (2018). Real-world use of omalizumab in patients with chronic idiopathic/spontaneous urticaria in the United States. Allergy and Asthma Proceedings. 39(3). 191–200. 10 indexed citations
7.
Sher, Ellen & William E. Berger. (2017). Efficacy Analysis of MP-AzeFlu Compared with Fluticasone Propionate Nasal Spray in Children 6 through 11 Years of Age with Allergic Rhinitis. Journal of Allergy and Clinical Immunology. 139(2). AB252–AB252.
8.
Chehade, Mirna & Ellen Sher. (2017). Medical therapy versus dietary avoidance in eosinophilic esophagitis: Which approach is better?. Allergy and Asthma Proceedings. 38(3). 170–176. 6 indexed citations
9.
Sher, Ellen, Sandra M. Gawchik, William E. Berger, & Eli O. Meltzer. (2016). Efficacy of MP-Azeflu in the Treatment of Postnasal Drip and Rhinorrhea in Patients with Seasonal Allergic Rhinitis (SAR). Journal of Allergy and Clinical Immunology. 137(2). AB260–AB260.
10.
Sher, Ellen, et al.. (2016). Cellular Mechanisms Contributing to Inadequate Response to Glucocorticoid Therapy.
11.
Sher, Ellen, et al.. (2014). Intranasal corticosteroids: The role of patient preference and satisfaction. Allergy and Asthma Proceedings. 35(1). 24–33. 12 indexed citations
12.
Sher, Ellen & Harry Sacks. (2006). Azelastine Nasal Spray Compared to Cetirizine in the Treatment of Patients with Seasonal Allergic Rhinitis: a Pooled Analysis of Two Double-Blind, Multicenter Studies.. Journal of Allergy and Clinical Immunology. 117(2). S319–S319. 2 indexed citations
13.
Leung, Donald Y.M., Richard J. Martin, Stanley J. Szefler, et al.. (1995). Dysregulation of interleukin 4, interleukin 5, and interferon gamma gene expression in steroid-resistant asthma.. The Journal of Experimental Medicine. 181(1). 33–40. 284 indexed citations
14.
Sher, Ellen, et al.. (1994). Steroid-resistant asthma. Cellular mechanisms contributing to inadequate response to glucocorticoid therapy.. Journal of Clinical Investigation. 93(1). 33–39. 318 indexed citations
15.
Szefler, S.J., et al.. (1993). Combination IL-2 and IL-4 reduces glucocorticoid receptor-binding affinity and T cell response to glucocorticoids.. The Journal of Immunology. 151(7). 3460–3466. 355 indexed citations
16.
Sher, Ellen, et al.. (1990). Effect of salbutamol on potassium influx in erythrocytes of allergic subjects and investigation of beta 2 receptor autoantibodies.. PubMed. 65(1). 63–8. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026